![](https://library.celltelligence.com/wp-content/uploads/2020/10/Novartis-Earnings.png)
$0
Kymriah’s Sales Remain Flat After US and EU Approvals in ≥3L FL, PHE885’s Submission Delayed to 2025; YTB323’s Development Strategy Being Updated; Novartis Q2 2022 Earnings Call Summary
On Tuesday, July 19, 2022, Novartis held their Q2 2022 earnings call (press release / presentation) highlighting Kymriah’s (CD19 CAR-T) approval in ≥3L FL, both in the US and EU. Additionally, PHE885’s (T-Charge BCMA CAR-T) submission has been delayed to 2025, while YTB323’s (T-Charge CD19 CAR-T) Ph3 trial development strategy is under review. Below, Celltelligence provides insights on Novartis’s potential strategies to increase Kymriah’s revenue, while discussing if the company could use their recently acquired Priority Review Voucher to accelerate their T-Charge programs.